MRNA
ModernaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The post-earnings bull read is that Q1 showed real top-line recovery, driven by international COVID sales and new European approvals, while R&D and SG&A both declined year over year and management reiterated 2026 growth and cost-discipline targets [#8-K-2026-05-01].
Posture
Defensive
Lead driver
Momentum
What changed
3 setup hits (3d) with net bullish as of 2026-06-03.
What can break
A $950 million settlement payment is expected in Q3 2026, creating a real cash outflow after the Q1 non-cash litigation charge [#8-K-2026-05-01].
Momentum
45
Value
41
Sentiment
46
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $43.00 · Bull $58.00 · Bear $30.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $41.16
Why
Momentum45 · Δ7d +0.9
Value41 · Δ7d +0.1
Sentiment46 · Δ7d +4.7
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
45
34% active weight
Current posture
7d trendImproving
Δ7d
+0.9
Δ21d
-19.7
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
46
33% active weight
Current posture
7d trendImproving
Δ7d
+4.7
Δ21d
+19.8
Why this grade
Composite grade D. Momentum 45.4 / Value 41.1 / Sentiment 45.7
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$18.11B
Beta
1.31
Shares Out
390.68M
P/E (TTM) · Derived
-6.4
P/S (TTM)
5.63
P/FCF (TTM) · Derived
-6.75
Rev YoY
-45.4%
EPS YoY
-1674.0%
Gross Margin
+63.5%
Op Margin
-155.2%
Net Debt
-$6.96B
Current Ratio
3.92
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology